Holen Sie sich die Stockscreener-App
1.49
5.67%
0.08
Handel nachbörslich:
1.49
Schlusskurs vom Vortag:
$1.41
Offen:
$1.43
24-Stunden-Volumen:
630.65K
Relative Volume:
0.69
Marktkapitalisierung:
$107.48M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-292.19M
KGV:
-0.3282
EPS:
-4.54
Netto-Cashflow:
$-208.41M
1W Leistung:
+7.97%
1M Leistung:
+12.03%
6M Leistung:
-38.68%
1J Leistung:
-50.83%
1-Tages-Spanne:
$1.42
$1.519
1-Wochen-Bereich:
$1.36
$1.5499
52-Wochen-Spanne:
$1.01
$5.44
Zentalis Pharmaceuticals Inc Stock (ZNTL) Company Profile
Firmenname
Zentalis Pharmaceuticals Inc
Sektor
Branche
Telefon
(858) 263-4333
Adresse
10275 SCIENCE CENTER DRIVE, SAN DIEGO, NY
Vergleichen Sie ZNTL mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ZNTL
Zentalis Pharmaceuticals Inc
|
1.49 | 101.71M | 0 | -292.19M | -208.41M | -4.54 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.92 | 99.42B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.55 | 58.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.52 | 56.35B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
646.60 | 39.02B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
307.51 | 34.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Zentalis Pharmaceuticals Inc Stock (ZNTL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-08-12 | Hochstufung | Wedbush | Underperform → Neutral |
| 2024-06-20 | Herabstufung | UBS | Buy → Neutral |
| 2024-06-18 | Herabstufung | Jefferies | Buy → Hold |
| 2024-06-18 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2024-06-18 | Herabstufung | Wedbush | Neutral → Underperform |
| 2024-06-18 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2023-11-08 | Herabstufung | Wedbush | Outperform → Neutral |
| 2023-11-07 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2022-07-12 | Eingeleitet | Cowen | Outperform |
| 2022-04-06 | Eingeleitet | Wells Fargo | Overweight |
| 2021-10-07 | Fortgesetzt | Jefferies | Buy |
| 2021-09-30 | Eingeleitet | Stifel | Buy |
| 2021-09-29 | Eingeleitet | Oppenheimer | Outperform |
| 2021-05-21 | Eingeleitet | UBS | Buy |
| 2021-01-20 | Eingeleitet | Wedbush | Outperform |
| 2020-09-29 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-08-27 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-04-28 | Eingeleitet | Guggenheim | Buy |
| 2020-04-28 | Eingeleitet | Jefferies | Buy |
| 2020-04-28 | Eingeleitet | Morgan Stanley | Overweight |
| 2020-04-28 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Zentalis Pharmaceuticals Inc Aktie (ZNTL) Neueste Nachrichten
Price Clustering Detected in Zentalis Pharmaceuticals Inc. StockMarket Risk Analysis & Fast Entry Momentum Alerts - 선데이타임즈
Using flow based indicators on Zentalis Pharmaceuticals Inc.July 2025 Outlook & Daily Growth Stock Investment Tips - Newser
Zentalis Pharmaceuticals Inc. stock outlook for YEARMarket Trend Report & AI Enhanced Trading Signals - Newser
Has Zentalis Pharmaceuticals Inc. Stock Ever Crashed Historical Volatility ReviewTrend Reversal Watch with Entry Signals - Newser
Applying Wyckoff theory to Zentalis Pharmaceuticals Inc. stockHigh Win Rate Strategy with Stop Protection - Newser
Is Zentalis Pharmaceuticals Inc. stock a smart retirement pickROI Focused Stock Opportunities - mustnews.co.kr
Can a trend reversal in Zentalis Pharmaceuticals Inc. lead to recoveryFree Top Gaining Picks With Entry Signals - Newser
How to integrate Zentalis Pharmaceuticals Inc. into portfolio analysis toolsTrade Setup Builder with Custom Alerts - Newser
Custom watchlist performance reports with Zentalis Pharmaceuticals Inc.Price Spike Prediction for Active Traders - Newser
Analyzing recovery setups for Zentalis Pharmaceuticals Inc. investorsFree Swing Trading Plan With Smart Signals - Newser
Using economic indicators to assess Zentalis Pharmaceuticals Inc. potentialFree Confirmed Setup With Expert Accuracy - Newser
Leerink Partnrs Has Pessimistic View of ZNTL Q3 Earnings - Defense World
Equities Analysts Offer Predictions for ZNTL Q3 Earnings - Defense World
When is the best time to exit Zentalis Pharmaceuticals Inc.Predictive AI Signals for Short-Term Trading - Newser
Wall Street Zen Upgrades Zentalis Pharmaceuticals (NASDAQ:ZNTL) to Hold - Defense World
Why Zentalis Pharmaceuticals Inc. stock attracts strong analyst attentionFree Trend Analysis for Safer Trades - Newser
Zentalis price target lowered to $5 from $6 at Wells Fargo - TipRanks
ZNTL: Wells Fargo Adjusts Price Target, Maintains Rating | ZNTL Stock News - GuruFocus
Zentalis Pharmaceuticals: Hold Rating Amid Delayed Catalysts and Market Skepticism - TipRanks
Strategic Advancements and Promising Clinical Data Support Buy Rating for Zentalis Pharmaceuticals - TipRanks
Zentalis Pharmaceuticals Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Sentiment analysis tools applied to Zentalis Pharmaceuticals Inc.Free Growth Focused Entry Plan Suggestions - Newser
Zentalis Pharmaceuticals Reports Improved Financial Results - TipRanks
Zentalis (ZNTL) Q2 Loss Narrows 70% - The Motley Fool
Zentalis (ZNTL) Q2 Loss Narrows 70% - AOL.com
Zentalis Pharmaceuticals: Navigating the Crossroads of Innovation and Financial Prudence - AInvest
Zentalis Pharmaceuticals Reports Q2 2025 Financial Results - TipRanks
Zentalis Pharmaceuticals Reports Second Quarter 2025 Financial Results and Operational Progress - GlobeNewswire
Zentalis Advances Revolutionary Ovarian Cancer Drug with $303M War Chest, FDA Fast-Track Potential - Stock Titan
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Given Average Recommendation of “Moderate Buy” by Brokerages - Defense World
51,061 Shares in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Bought by Universal Beteiligungs und Servicegesellschaft mbH - Defense World
Real time social sentiment graph for Zentalis Pharmaceuticals Inc.Free Portfolio Diversification Stock Ideas - Newser
Zentalis Pharmaceuticals Inc expected to post a loss of 53 cents a shareEarnings Preview - TradingView
When is Zentalis Pharmaceuticals Inc. stock expected to show significant growthSkyrocketing profit margins - Jammu Links News
What is the risk reward ratio of investing in Zentalis Pharmaceuticals Inc. stockHigh-octane financial growth - Jammu Links News
Finanzdaten der Zentalis Pharmaceuticals Inc-Aktie (ZNTL)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):